ProCE Banner Activity

New Developments in Systemic Therapy for Early-Stage NSCLC Management: Expert Answers to Your Questions

Clinical Thought

Are you up to date on the latest management of patients with early-stage NSCLC using approved systemic therapy options? Read this expert commentary addressing healthcare provider questions on key points that you should know.

Released: November 08, 2024

Expiration: November 07, 2025

Share

Faculty

Beth Sandy

Beth Sandy, MSN, CRNP, FAPO

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by PACE In partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Faculty Disclosure

Primary Author

Beth Sandy, MSN, CRNP, FAPO

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Beth Sandy, MSN, CRNP, FAPO: consultant/advisor/speaker: Amgen, AstraZeneca, Janssen, Jazz, Lilly, Merck, Pfizer, Takeda.